Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arovella Therapeutics Ltd

ALA.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.04

▼ -4.76%

Market Cap $52.33M · Vol 340.35K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$52.33M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

38.46

Momentum

Beta

0.88

vs Market

52W High

$0.09

47.49% below

52W Low

$0.04

6.17% above

Volume

340.35K

Avg 618.72K

P/B

5.30

Price-to-book

ROE

N/A

Return on equity

Free Float

76.17%

Public shares

Shariah Compliance8 STANDARDS

✗ Arovella Therapeutics Ltd (ALA.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALA.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-1.64%

-13.04%

-22.08%

YTD

-35.48%

-25.00%

+1.35%

+13.21%

Financials & Valuation

TTM · Annual

Total Revenue	$553.54K
Net Income	$-4,785,477.00
Revenue Growth (YoY)	+166.07%
Gross Margin	100.00%
Operating Margin	-1,301.77%
Net Profit Margin	-864.52%
ROE	N/A
ROA · ROIC	-37.78% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	93.09
P/B	5.30
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.21B

Technical Indicators

50-Day SMA	$0.05
200-Day SMA	$0.05
RSI (14)	38.46
Beta	0.88
52-Week High	$0.09
52-Week Low	$0.04

Volume Today	340.35K
Avg Daily Volume (30D)	618.72K
Relative Volume	0.55x
Volatility (10D)	32.11
Volatility (30D)	37.08
Free Float	76.17%

Analyst Consensus

N/A

Current Price $0.04

Mean Target N/A

52W Low$0.04 52W High$0.09

Current

Target

$0.04 $0.09

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SJX1S6

ISINAU0000182784

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -0.41% ARGX argenx SE -2.52% INSM Insmed Inc -1.11% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. It is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. It focuses on integrating IL-12-TM technology into its solid tumor programs.